Ira Erlichman1, Oded Breuer2, David Shoseyov2, Malena Cohen-Cymberknoh2, Benjamin Koplewitz3, Diana Averbuch4, Matti Erlichman5, Elie Picard6, Eitan Kerem2. 1. Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2. Pediatric Pulmonology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Pediatric Radiology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 4. Pediatric Infectious Disease Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 5. Department of Pediatric Emergency Medicine, Shaare Zedek Medical Center, Jerusalem, Israel. 6. Pediatric Pulmonology Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
Abstract
The incidence of pediatric community acquired complicated pneumonia (PCACP) is increasing. Questions addressed: Are different types of PCACP one disease? How do different treatment protocols affect the outcome? METHODS: Retrospective analysis of medical records of PCACP hospitalizations in the three major hospitals in Jerusalem in the years 2001-2010 for demographics, clinical presentation, management, and outcome. RESULTS: Of the 144 children (51% aged 1-4 years), 91% of Jewish origin; 40% had para-pneumonic effusion (PPE), 40% empyema (EMP), and 20% necrotizing pneumonia (NP). Bacterial origin was identified in 42% (empyema 79%, P = 0.009), most common S. pneumoniae (32%), group A streptococcus (9%). Patients with EMP, compared to PPE and NP, were less likely to receive prior antibiotic treatment (35% vs. 57% and 59%, respectively, P = 0.04). Mean hospitalization was longer in patients with NP followed by EMP and PPE (16.4 ± 10.6, 15.2 ± 7.9, and 12.7 ± 4.7 days, respectively), use of fibrinolysis was not associated with the outcome. All children had recovered to discharge regardless of antibiotic therapy or fibrinolysis. ANSWER: NP is a more severe disease with prolonged morbidity and hospitalization in spite of prior antibiotic treatment. All types had favorable outcome regardless of treatment-protocol. Complicated pneumonia has an ethnic predominance. Pediatr Pulmonol. 2017;52:247-254.
The incidence of pediatric community acquired complicated pneumonia (PCACP) is increasing. Questions addressed: Are different types of PCACP one disease? How do different treatment protocols affect the outcome? METHODS: Retrospective analysis of medical records of PCACP hospitalizations in the three major hospitals in Jerusalem in the years 2001-2010 for demographics, clinical presentation, management, and outcome. RESULTS: Of the 144 children (51% aged 1-4 years), 91% of Jewish origin; 40% had para-pneumonic effusion (PPE), 40% empyema (EMP), and 20% necrotizing pneumonia (NP). Bacterial origin was identified in 42% (empyema 79%, P = 0.009), most common S. pneumoniae (32%), group A streptococcus (9%). Patients with EMP, compared to PPE and NP, were less likely to receive prior antibiotic treatment (35% vs. 57% and 59%, respectively, P = 0.04). Mean hospitalization was longer in patients with NP followed by EMP and PPE (16.4 ± 10.6, 15.2 ± 7.9, and 12.7 ± 4.7 days, respectively), use of fibrinolysis was not associated with the outcome. All children had recovered to discharge regardless of antibiotic therapy or fibrinolysis. ANSWER: NP is a more severe disease with prolonged morbidity and hospitalization in spite of prior antibiotic treatment. All types had favorable outcome regardless of treatment-protocol. Complicated pneumonia has an ethnic predominance. Pediatr Pulmonol. 2017;52:247-254.
Authors: Lauge Farnaes; Julianne Wilke; Kathleen Ryan Loker; John S Bradley; Christopher R Cannavino; David K Hong; Alice Pong; Jennifer Foley; Nicole G Coufal Journal: Diagn Microbiol Infect Dis Date: 2019-02-02 Impact factor: 2.803
Authors: Emily Allin; Nassr Nama; Michael A Irvine; Colleen Pawliuk; Marie Wright; Matthew Carwana Journal: BMJ Open Date: 2021-03-24 Impact factor: 2.692
Authors: L Golden; S Chaya; K Reichmuth; A Visagie; A Ayuk; S Kwarteng Owusu; D Marangu; N Affendi; A Lakhan; D Gray; A Vanker; H Zar; M Zampoli Journal: Afr J Thorac Crit Care Med Date: 2021-12-31